Plain-English translation of NCT06917092 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new immunotherapy drug called QL1706, given together with chemotherapy (with or without an anti-angiogenic drug), in patients whose endometrial cancer has spread or come back and no longer responds to previous immunotherapy treatments. The researchers want to see whether this combination can shrink tumors and help patients live longer. You would receive the treatment over several months while doctors monitor how well it works and track any side effects.
When endometrial cancer spreads or returns, doctors use immunotherapy drugs to help the body's immune system fight the cancer. However, some patients' cancers stop responding to these treatments. This trial exists to find a new option for those patients—combining QL1706 with chemotherapy to try to restart the cancer-fighting response.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital or clinic regularly to receive the medication intravenously (through an IV). Your treatment would consist of QL1706 combined with chemotherapy, and your doctor may also add an anti-angiogenic drug depending on what they think is best for you. Throughout your treatment, you would have blood tests and imaging scans to check how your cancer is responding and to monitor for any side effects. After your treatment ends, you would continue to have follow-up visits and scans to track your health and survival.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment target
~30 participants
Started
May 2025
Primary completion
April 2027
Age range
18 Years – 70 Years
Sex
Female only
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wen X Liu, Doctor
Tianjin Medical University Cancer Institute and Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.